NASDAQ · CLYM
Climb Bio, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CLYM: Nov 5, 2026
Climb Bio, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 8 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.2. The reported EPS for the same quarter last year was $-0.19.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.20 | $-0.16 | $-0.25 | 8 |
| Dec 2026 | $-0.22 | $-0.16 | $-0.33 | 8 |
| Mar 2027 | $-0.23 | $-0.21 | $-0.25 | 5 |
| Jun 2027 | $-0.25 | $-0.24 | $-0.26 | 5 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · Zacks · BNK Invest · MarketBeat- Fintel · Oct 26, 7:52 AM EDTClimb Bio, Inc. Announces Initial PrisMN Phase 2 Data for Budoprutug in Primary Membranous NephropathyClimb Bio, Inc. announced initial PrisMN Phase 2 data for budoprutug, its anti-CD19 monoclonal antibody, in primary membranous nephropathy (“pMN”). PrisMN is an ongoing Phase 2 dose-escalation trial evaluating budoprutug at three dose levels (200 mg, 600 mg and 1000 m
- Fintel · Oct 23, 9:18 PM EDTClimb Bio, Inc. and Mabworks Announce CLYM116/MIL116 Data Demonstrating ~70% Gd-IgA1 ReductionOn October 23, 2026, Climb Bio, Inc. and Beijing Mabworks Biotech Co., Ltd. announced additional Phase 1 data in healthy volunteers for CLYM116/MIL116, an anti-APRIL monoclonal antibody in development for IgA nephropathy. CLYM116 is being evaluated in complementary Phase 1 trials
- Zacks · Oct 20, 8:40 AM EDTAre Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?Here is how Climb Bio, Inc. (CLYM) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
- Fintel · Sep 15, 6:12 AM EDTClimb Bio Consensus Price Target Raised 21.88% to $28.41The average one-year price target for Climb Bio (NASDAQGM:CLYM) has been revised to $28.41 / share from $23.31 (prior estimate dated August 25, 2026), an increase of 21.88%. These figures represent aggregate analyst targets compiled from multiple sources and do not constitute a r
- BNK Invest · Sep 4, 3:50 PM EDTNoteworthy Friday Option Activity: TYRA, CLYM, AVBPAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Tyra Biosciences Inc (Symbol: TYRA), where a total of 7,130 contracts have traded so far, representing approximately 713,000 underlying shares. That amounts to about 160
- MarketBeat · Sep 3, 2:02 PM EDTClimb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy DrugClimb Bio (NASDAQ:CLYM) presented phase I data for CLYM116, an anti-APRIL “sweeper” antibody being developed for IgA nephropathy, and said the results support advancing the program into an ongoing phase II study in China. The company said CLYM116 is designed to bind circulating
- RTTNews · Sep 3, 7:20 AM EDTClimb Bio Shares Rise On CLYM116 Data Supporting Every-12-Week Dosing(RTTNews) – Climb Bio, Inc. (CLYM) announced positive initial Phase 1 data for CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy (IgAN), showing a prolonged half-life and deep, durable suppression of APRIL, IgA and Gd-IgA1.
- BNK Invest · Aug 24, 3:32 PM EDTNotable Monday Option Activity: BA, TTWO, CLYMLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Boeing Co. (Symbol: BA), where a total volume of 62,160 contracts has been traded thus far today, a contract volume which is representative of approximately 6.2
- Zacks · Jul 8, 9:40 AM EDTIs Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?Here is how Artiva Biotherapeutics, Inc. (ARTV) and Climb Bio, Inc. (CLYM) have performed compared to their sector so far this year.
- RTTNews · Jul 6, 5:51 AM EDT5 Biotech Stocks That Delivered 100% To 300% Gains: Did Your Winning Trades Offset Portfolio Losses?(RTTNews) – Even with strong research and disciplined stock selection, an investor may not get every stock pick right. As legendary investor Peter Lynch once said, "In this business, if you're good, you're right six times out of ten. You're never going to be right nine times out
- MarketBeat · May 21, 1:02 AM EDTClimb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnectClimb Bio (NASDAQ:CLYM) outlined its clinical development strategy and upcoming data readouts during a fireside chat at H.C. Wainwright’s BioConnect Conference, with management emphasizing two biologic drug programs aimed at immune-mediated diseases, including nephrology and hema
- Fintel · May 14, 2:22 AM EDTClimb Bio (CLYM) Price Target Increased by 18.34% to 19.62The average one-year price target for Climb Bio (NasdaqGM:CLYM) has been revised to $19.62 / share. This is an increase of 18.34% from the prior estimate of $16.58 dated April 25, 2026. The price target is an average of many targets provided by analysts. The l
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Climb Bio, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.